title: Specific IgA subclass responses in serum and saliva: a 12-month follow-up study after parenteral booster immunization with tetanus toxoid.
abstract: Specific IgA subclass antibodies against tetanus toxoid in serum, parotid saliva, and whole saliva were quantified after booster immunization. Samples from 14 healthy individuals were collected before and 1, 6, and 12 months after subcutaneous injection with Duplex (0.23 ml tetanus toxoid 30 Lf/mL and diphtheria 7.3 Lf/mL). Samples of whole saliva were also collected after 2 weeks. Specific IgA1 and IgA2 subclass antibodies to tetanus toxoid were quantified by enzyme-linked immunosorbent assay (ELISA). In this quantitative method, chimeric IgA1 and IgA2 antibodies directed against NP (4-hydroxy-3-nitrophenacetyl) were used as standards. Total levels of IgA1 and IgA2 were measured using a nephalometer or ELISA. Immunization with tetanus toxoid resulted in raised mean values of specific IgA1 and IgA2 antibodies against tetanus toxoid in serum after 1 month. Compared with the baseline, the mean value of specific IgA1 antibodies showed a 2.6-fold increase (mean value 10.47 microgram/mL) in serum, and that of specific IgA2 antibodies a 2.7-fold increase (mean value 0.93 microgram/mL). Specific IgA subclass antibody levels in parotid and whole saliva were unchanged after 1 month. The ratio of specific IgA subclass antibodies to total IgA subclass antibodies was 3 to 10 times higher in parotid saliva compared with whole saliva. In conclusion, subcutaneous booster immunization with tetanus toxoid induced immune responses of both antigen-specific IgA1 and IgA2 subclass antibodies in serum with the same increase, whereas the levels of specific IgA subclass antibodies in secretory fluids were unchanged. The ratio of specific IgA subclass antibodies to immunoglobulins was higher in parotid saliva compared with whole saliva.
authors.affiliation: Department of Microbiology, Pathology and Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden. Per-Erik.Engstrom@impi.ki.se
authors.forename: Per-Erik
authors.initials: PE
authors.lastname: Engström
authors.forename: Rolf
authors.initials: R
authors.lastname: Gustafson
authors.forename: Mitra
authors.initials: M
authors.lastname: Granberg
authors.forename: Gunilla Norhagen
authors.initials: GN
authors.lastname: Engström
mesh_terms: D000328:Adult; D000907:Antibodies, Bacterial / Q000032:analysis / Q000097:blood / Q000145:classification; D000917:Antibody Formation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D018928:Immunity, Mucosal; D007117:Immunization, Secondary; D007070:Immunoglobulin A / Q000097:blood* / Q000145:classification; D007071:Immunoglobulin A, Secretory / Q000032:analysis*; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010306:Parotid Gland / Q000378:metabolism; D012463:Saliva / Q000276:immunology*; D013745:Tetanus Toxoid / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D007070:Immunoglobulin A; D007071:Immunoglobulin A, Secretory; D013745:Tetanus Toxoid